Neuronetics presented new real-world evidence from its TrakStar patient database at the 2026 Clinical TMS Society Annual Meeting. Two posters covered NeuroStar TMS effectiveness for major depressive disorder by age and biological sex, and real-world antidepressant outcomes in adolescents aged 12–14. A June 6 plenary focused on keeping patients well with TMS maintenance therapy, an area of growing clinical and payer interest.
The adolescent 12–14 data is notable because NeuroStar's current FDA clearance covers adolescents 15 and older, so evidence in younger patients could support a future indication expansion.
Neuronetics also demonstrated NeuroStar neuronavigation at the CTMSS PULSES training course, enabled by its recently announced partnership with ANT Neuro to integrate the visor2 neuronavigation system, with broader rollout planned for the second half of 2026. The company was a Silver Sponsor of the meeting.
For clinics, the maintenance-therapy and age/sex effectiveness data add to the real-world evidence base used in payer discussions and patient counseling.
Source
Reporting based on coverage from Neuronetics. This article is editorial summary intended for general information; it is not medical advice.
